Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...181182183184185186187188189190191...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion, Trial completion date, Trial primary completion date:  EASE: An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Dec 10, 2019   
    P2,  N=52, Completed, 
    Further study is needed to validate the efficacy of this combination. Recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Jun 2019 --> Dec 2018
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Metastases:  First-line Chemotherapy for Recurrent Cervical Cancer (clinicaltrials.gov) -  Dec 8, 2019   
    P2,  N=37, Recruiting, 
    Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2021 Not yet recruiting --> Recruiting
  • ||||||||||  hetrombopag (SHR 8735) / Jiangsu Hengrui Medicine
    Journal:  Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. (Pubmed Central) -  Dec 6, 2019   
    Orally administered hetrombopag specifically promoted the viability and growth of 32D-MPL cells in hollow fibres implanted into nude mice with much higher potency than that of the well-known TPOR agonist, eltrombopag, in association with activation of TPOR-dependent signal transduction in vivo. Taken together, our findings indicate that, given its favourable pharmacological characteristics, hetrombopag may represent a new, orally active, small-molecule TPOR agonist for patients with thrombocytopenia.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion, Trial completion date:  Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC (clinicaltrials.gov) -  Dec 4, 2019   
    P=N/A,  N=20, Completed, 
    Anti-PD-1 antibody SHR-1210 shows encouraging efficacy in patients with advanced gastric/GEJ cancer in China, including mismatch repair-proficient subgroups. Recruiting --> Completed | Trial completion date: Jul 2020 --> Nov 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial completion date, Trial primary completion date:  CARES-310: A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC (clinicaltrials.gov) -  Dec 3, 2019   
    P3,  N=510, Recruiting, 
    Recruiting --> Completed | Trial completion date: Jul 2020 --> Nov 2019 Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Dec 2021
  • ||||||||||  AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial primary completion date:  A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) -  Dec 2, 2019   
    P1,  N=51, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Dec 2021 Trial primary completion date: Jun 2020 --> Feb 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Retrospective data, Journal:  Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status. (Pubmed Central) -  Nov 27, 2019   
    In addition, PS status was shown as the only independently significant factor to influence the OS (P = .049). Fatigue (82.6%), appetite decrease (73.9%), and anemia (69.6%) appeared to be the most common adverse events at any grade during the therapy of apatinib.The outcomes of the present study revealed that therapeutic model of careful dose modification of apatinib therapy initiated with low dose plus BSC as third or further-line treatment might be more beneficial on survival time comparing to BSC alone in patients with aGC of poor PS, however, as well as apparent adverse events.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment status:  mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer (clinicaltrials.gov) -  Nov 26, 2019   
    P3,  N=300, Enrolling by invitation, 
    Fatigue (82.6%), appetite decrease (73.9%), and anemia (69.6%) appeared to be the most common adverse events at any grade during the therapy of apatinib.The outcomes of the present study revealed that therapeutic model of careful dose modification of apatinib therapy initiated with low dose plus BSC as third or further-line treatment might be more beneficial on survival time comparing to BSC alone in patients with aGC of poor PS, however, as well as apparent adverse events. Recruiting --> Enrolling by invitation
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Spherazole (itraconazole) / RA Chem, JW Pharma, Spherics
    PK/PD data, Journal:  Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole. (Pubmed Central) -  Nov 22, 2019   
    In summary, a strong CYP3A4 inducer (rifampin) had a strong effect (>5-fold) on the clinical pharmacokinetics of apatinib, whereas a strong CYP3A inhibitor (itraconazole 100 mg once a day) had a weak effect (1.25- to 2-fold). Whether these effects are of clinical significance needs further research and information about the exposure-safety and exposure-efficacy relationship of apatinib.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal:  Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. (Pubmed Central) -  Nov 19, 2019   
    Our findings suggested that apatinib is a highly potent, oral active anti-angiogenic, and anti-HCC agent. The results from current study provide a clear biological rationale to evaluate apatinib as a new agent in HCC in clinical setting, especially for the VEGFR-2 overexpression ones.
  • ||||||||||  Tykerb (lapatinib) / Novartis, pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine, Nerlynx (neratinib) / Puma
    Clinical, Review, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal:  Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. (Pubmed Central) -  Nov 17, 2019   
    Currently, specific monoclonal antibodies and tyrosine kinase inhibitors (TKIs) are the two HER2 targeting strategies that have successfully improved the prognosis of patients with HER2-positive breast cancer. This paper focuses on three officially approved TKIs for HER2 breast cancer, namely, lapatinib, neratinib and pyrotinib, and systematically reviews the mechanism, safety, efficacy and resistance of these TKIs.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date:  A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) -  Nov 15, 2019   
    P1,  N=99, Active, not recruiting, 
    This paper focuses on three officially approved TKIs for HER2 breast cancer, namely, lapatinib, neratinib and pyrotinib, and systematically reviews the mechanism, safety, efficacy and resistance of these TKIs. Trial completion date: Mar 2019 --> Oct 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment change, Trial completion date, Trial primary completion date:  Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA (clinicaltrials.gov) -  Nov 15, 2019   
    P2,  N=37, Recruiting, 
    Trial completion date: Mar 2019 --> Oct 2019 N=66 --> 37 | Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    New P1 trial:  SHR0302 and Steroid As First Line Therapy for Chronic GVHD (clinicaltrials.gov) -  Nov 14, 2019   
    P1,  N=30, Not yet recruiting, 
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date, Tumor mutational burden:  EBVaGC-SYSUCC: PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. (clinicaltrials.gov) -  Nov 14, 2019   
    P2,  N=20, Enrolling by invitation, 
    Trial completion date: Jun 2021 --> Jun 2022 | Initiation date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2020 --> Dec 2020 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  verinurad (RDEA3170) / AstraZeneca, Zurampic (lesinurad) / AstraZeneca, SHR 4640 / Jiangsu Hengrui Medicine
    Journal:  Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). (Pubmed Central) -  Nov 10, 2019   
    Meanwhile, the introduction of sulfonyl group into small molecules has become one of the important strategies for structural optimization of URAT1 inhibitors. Furthermore, developing drug candidates targeting both URAT1 and xanthine oxidase (XOD) has attracted lots of interest and attention.